Growth Hormone, Cardiovascular Risk, and Visceral Adiposity

Completed · Not applicable · Has a placebo group

Conditions studied: Obesity

In brief

This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be administered and effects on cardiovascular risk, insulin resistance and body composition will be measured.

Key facts

Study ID

NCT00131378

Run by

Massachusetts General Hospital

People needed

142

Starts

2004-11-01

Expected to finish

2013-06-01

Last updated by the study team

2016-03-11

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• For growth hormone measurement part (for men and women):
• For visceral adiposity arm: waist circumference greater than or equal to 88 cm for women or 102 cm for men, and BMI greater than or equal to 25 kg/m2
• For lean controls: BMI 18.5 to 24.9 kg/m2
• For growth hormone treatment part (for men and women):
• Visceral adiposity (waist circumference greater than or equal to 88 cm for women and 102 for men, BMI greater than or equal to 25 kg/m2)
• IGF-I within the lowest 2 quartiles for age and gender
• Willingness to maintain current activity level and diet

You may not qualify if…

• Diabetes mellitus (fasting plasma glucose greater than 126 mg/dL or 2-hour post-oral glucose tolerance test [OGTT] plasma glucose greater than 200)
• Taking the following medications in the last 3 months: weight loss or lipid-lowering agents, medications to treat diabetes mellitus or "pre-diabetes", oral contraceptives or estrogen-containing medications, other medications known to significantly affect weight
• Smoking
• Hematocrit below the lower limit of normal
• Amenorrhea for 3 months (in women)
• Pregnant or breastfeeding (in women)
• Polycystic ovary syndrome (in women)
• Weight that exceeds 280 pounds
• SGPT greater than 2 times the upper limit of normal
• History of malignancy, except for fully resolved basal cell carcinomas of the skin (Specific Aim 2 only)
• Radiation exposure greater than 1000 mrem over the last 12 months
• Previous diagnosis of cardiovascular disease
• History of pituitary or hypothalamic disease, brain radiation, or childhood growth hormone deficiency
• History of carpal tunnel syndrome that has not been surgically treated

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.